share_log

Harvard Bioscience Q3 2024 Adj. EPS $(0.02) Misses $0.03 Estimate, Sales $22.000M Miss $25.300M Estimate

Harvard Bioscience Q3 2024 Adj. EPS $(0.02) Misses $0.03 Estimate, Sales $22.000M Miss $25.300M Estimate

哈佛生物科學 2024年第三季度調整後每股收益爲$(0.02),低於$0.03的預估,銷售額爲2200萬美元,低於2530萬美元的預估
Benzinga ·  2024/11/07 20:06

Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.03 by 166.67 percent. The company reported quarterly sales of $22.000 million which missed the analyst consensus estimate of $25.300 million by 13.04 percent. This is a 13.26 percent decrease over sales of $25.363 million the same period last year.

哈佛生物科學(納斯達克:HBIO)每股虧損$(0.02),低於分析師一致預期的$0.03,跌幅爲166.67%。該公司報告的季度銷售額爲2200萬美元,低於分析師一致預期的2530萬美元,跌幅爲13.04%。與去年同期的2536.3萬美元的銷售額相比,下降了13.26%。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論